Clinical Study on the Safety and Efficacy of QY-1-T in the Treatment of HBV-associated Advanced HCC

NARecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 26, 2024

Primary Completion Date

July 31, 2025

Study Completion Date

October 30, 2025

Conditions

Liver Cancer

Interventions

DRUG

QY-1-T

QY-1-T is a TCR-T drug targeting HBV-related HCC

Trial Locations (1)

RECRUITING

Shanghai General Hospital, Shanghai

All Listed Sponsors

collaborator

Shenzhen Zhongke Qiyuan Biotechnology Co., Ltd.

UNKNOWN

lead

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER